GIGA 2021 Annual Report 73 SELECTED PUBLICATIONS Monitoring of a progressive functional dopaminergic deficit in the A53T-AAV synuclein rats by combining 6-[18F]fluoro-L-m-tyrosine imaging and motor performances analysis. G. Becker G, Michel A, Bahri MA, Mairet-Coello G, Lemaire C, Deprez T, Freyssin A, Jacquin L, Hustadt F, De Wolf C, Caruso M, Frequin JM, Gillent E, Bezard E, Garraux G, Luxen A, Citron M, Downey P, Plenevaux A. Neurobiol Aging. 2021 Nov;107:142-152. Tumor Microenvironment Modifications Recorded With IVIM Perfusion Analysis and DCE-MRI After Neoadjuvant Radiotherapy: A Preclinical Study. Lallemand F, Leroi N, Blacher S, Bahri MA, Balteau E, Coucke P, Noël A, Plenevaux A and Martinive P. Front Oncol. 2021 Dec 21;11:784437. Parkinson’s disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI. Depierreux F, Parmentier E, Mackels L, Baquero K, Degueldre C, Balteau E, Salmon E, Phillips C, Bahri MA, Maquet P & Garraux G. NPJ Parkinsons Dis. 2021 Jul 8;7(1):57. Early brainstem [18F]THK5351 uptake is linked to cortical hyperexcitability in healthy aging. Van Egroo M, Chylinski D, Narbutas J, Besson G, Muto V, Schmidt C, Marzoli D, Cardone P, Vandeleene N, Grignard M, Luxen A, Salmon E, Lambert C, Bastin C, Collette F, Phillips C, Maquet P, Bahri MA, Balteau E, Vandewalle G. JCI Insight. 2021 Jan 25;6(2):e142514. In vivo exploration of synaptic projections in frontotempral dementia. Salmon E, Bahri MA, Plenevaux A, Becker G, Seret A, Delhaye E, Degueldre C, Balteau E, Lemaire C, Luxen A, Bastin C. Sci Rep. 2021 Aug 9;11(1):16092. IBA, ELYSIA In order to detect cardiac lesions or to assess pumping capacity, PET imaging can provide an accurate diagnosis and help to define the best treatment. In order to make this technology more accessible in hospitals, IBA, Elysia and the Universities of Liège and Louvain-la-Neuve have decided to pool their resources and technological expertise to work on the next generation of 13NH3 production solution for cardiac applications. GIGA-CRC’s role in this project was to produce 13NH3 via its cyclotron from a target dedicated to this isotope and via a shielded cell adapted to this application. The produced 13NH3 was then used by the company Elysia to develop a purification and quality control process in order to make an injectable radiopharmaceutical for humans.
RkJQdWJsaXNoZXIy MTk1ODY=